Feb 26 (Reuters) - Mayne Pharma Group Ltd MYX.AX:
H1 GROSS MARGIN 53%
H1 REVENUE AUD 94.3 MILLION
H1 GROSS PROFIT AUD 76.9 MILLION
H1 ADJUSTED EBITDA AUD 31 MILLION
COMPANY EXPECTS TO GROW UNDERLYING EBITDA IN 2HFY25 VIA REVENUE GROWTH
Further company coverage: MYX.AX
((Reuters.Briefs@thomsonreuters.com;;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.